181 related articles for article (PubMed ID: 25642445)
21. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
22. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
24. Atypical femoral fracture in the setting of alendronate treatment for osteoporosis: a case report and literature review.
Van Baarsel ED; Patel V; Kesbeh Y; Kahf H; Alonzo N
J Community Hosp Intern Med Perspect; 2019; 9(4):340-343. PubMed ID: 31528285
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
[TBL] [Abstract][Full Text] [Related]
26. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
[TBL] [Abstract][Full Text] [Related]
27. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
Huang HT; Kang L; Huang PJ; Fu YC; Lin SY; Hsieh CH; Chen JC; Cheng YM; Chen CH
Menopause; 2012 Dec; 19(12):1360-3. PubMed ID: 22968250
[TBL] [Abstract][Full Text] [Related]
28. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats.
Rhee Y; Won YY; Baek MH; Lim SK
J Bone Miner Res; 2004 Jun; 19(6):931-7. PubMed ID: 15125792
[TBL] [Abstract][Full Text] [Related]
29. Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis?
Doggrell SA
Expert Opin Pharmacother; 2004 Apr; 5(4):955-8. PubMed ID: 15102578
[TBL] [Abstract][Full Text] [Related]
30. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
Dobnig H
Expert Opin Pharmacother; 2004 May; 5(5):1153-62. PubMed ID: 15155114
[TBL] [Abstract][Full Text] [Related]
31. Bisphosphonates: preclinical aspects and use in osteoporosis.
Fleisch HA
Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
[TBL] [Abstract][Full Text] [Related]
32. Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture.
Iizuka Y; Takechi R; Iizuka H; Omodaka T; Takagishi K
Skeletal Radiol; 2016 Oct; 45(10):1403-7. PubMed ID: 27402027
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
Miller PD; McCarthy EF
Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
[TBL] [Abstract][Full Text] [Related]
34. Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate.
Khan MP; Singh AK; Singh AK; Shrivastava P; Tiwari MC; Nagar GK; Bora HK; Parameswaran V; Sanyal S; Bellare JR; Chattopadhyay N
J Bone Miner Res; 2016 Mar; 31(3):615-29. PubMed ID: 26391310
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
36. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
Hodsman A; Adachi J; Olszynski W
CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
38. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.
Sato M; Westmore M; Ma YL; Schmidt A; Zeng QQ; Glass EV; Vahle J; Brommage R; Jerome CP; Turner CH
J Bone Miner Res; 2004 Apr; 19(4):623-9. PubMed ID: 15005850
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonate treatment of osteoporosis.
Watts NB
Clin Geriatr Med; 2003 May; 19(2):395-414. PubMed ID: 12916293
[TBL] [Abstract][Full Text] [Related]
40. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
Lee YS; Gupta R; Kwon JT; Cho DC; Seo YJ; Seu SY; Park EK; Han I; Kim CH; Sung JK; Kim KT
Spine J; 2018 Oct; 18(10):1877-1887. PubMed ID: 29793000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
